Showing 3121-3130 of 3315 results for "".
- Surgical Specialties Launches Caliber Ophthalmics Division to Focus on Global Growth of Ophthalmic Surgical Procedureshttps://modernod.com/news/surgical-specialties-launches-caliber-ophthalmics-division-to-focus-on-global-growth-of-ophthalmic-surgical-procedures/2476597/Surgical Specialties Corporation (SSC) announced the launch of Caliber Ophthalmics, a new business division that combines SSC’s Sharpoint brand with its two recent ophthalmic acquisitions, Unique Technologies and VPM Surgical. To lead the Caliber Ophthalmics division, SSC has named <
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- The Winning Pitch Challenge Featured at ASCRShttps://modernod.com/news/the-winning-pitch-challenge-featured-at-ascrs/2476539/The Winning Pitch Challenge will feature contestants with innovative ophthalmic ideas presenting to a panel of industry leaders on Sunday, May 5 at the annual American Society of Cataract and Refractive Surgery (ASCRS) conference in San Dieg
- IBM’s New AI Technique Could Detect Glaucoma Earlierhttps://modernod.com/news/ibms-new-ai-technique-could-detect-glaucoma-earlier/2476530/At ARVO, IBM researchers presented new techniques in deep learning that could help unlock earlier glaucoma detection. IBM and NYU’s research demonstrates how deep learning models can be trained to learn from and analyze easily-obtained retina images, and then use this analysis to directly estimat
- Staar Surgical Announces Expanded Recommended Diopter Range for EVO Visian ICL in Germany and Japanhttps://modernod.com/news/staar-surgical-announces-expanded-recommended-diopter-range-for-evo-visian-icl-in-germany-and-japan/2476531/Staar Surgical announced that leading refractive ophthalmic societies in Germany and Japan have increased the diopter range for recommended use of phakic refractive lenses, including the EVO Visian ICL, to -3.0 diopters from -6.0 diopters. The German society, the Kommission Refraktive Chir
- Jim Wachtman Joins CorneaGen as Chief Commercial Officerhttps://modernod.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate
- RadianceTx Expands Team to Develop Beta Ophthalmic Systemhttps://modernod.com/news/radiancetx-expands-team-to-develop-beta-ophthalmic-system/2476511/Radiance Therapeutics has announced the expansion of its core team. Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Business Development and Outreach. James Fazio, MBA, Msc Eng, formerly Global Business Leader for
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar